Discounted Cash Flow (DCF) Analysis Levered
Cognition Therapeutics, Inc. (CGTX)
$2.94
+0.01 (+0.34%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|
Revenue (%) | |||||||||
Operating Cash Flow | - | - | - | - | - | - | - | - | - |
Operating Cash Flow (%) | |||||||||
Capital Expenditure | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) | |||||||||
Free Cash Flow | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 2.94 |
---|---|
Beta | 0.000 |
Diluted Shares Outstanding | 23.64 |
Cost of Debt | |
Tax Rate | 0.00 |
After-tax Cost of Debt | 3.32% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 3.784 |
Total Debt | 0.84 |
Total Equity | 69.50 |
Total Capital | 70.35 |
Debt Weighting | 1.20 |
Equity Weighting | 98.80 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - | - | - | - |
Capital Expenditure | - | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - | - |
WACC | |||||||||
PV LFCF | - | - | - | - | - | - | - | - | - |
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 3.78 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -40.72 |
Equity Value | - |
Shares Outstanding | 23.64 |
Equity Value Per Share | - |